HomeCompareZEOOF vs ABBV

ZEOOF vs ABBV: Dividend Comparison 2026

ZEOOF yields 5.10% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ZEOOF wins by $6876.10M in total portfolio value
10 years
ZEOOF
ZEOOF
● Live price
5.10%
Share price
$9.35
Annual div
$0.48
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$6876.20M
Annual income
$6,626,566,862.72
Full ZEOOF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — ZEOOF vs ABBV

📍 ZEOOF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZEOOFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZEOOF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZEOOF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZEOOF
Annual income on $10K today (after 15% tax)
$433.45/yr
After 10yr DRIP, annual income (after tax)
$5,632,581,833.31/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, ZEOOF beats the other by $5,632,560,777.31/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZEOOF + ABBV for your $10,000?

ZEOOF: 50%ABBV: 50%
100% ABBV50/50100% ZEOOF
Portfolio after 10yr
$3438.15M
Annual income
$3,313,295,817.24/yr
Blended yield
96.37%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

ZEOOF
Analyst Ratings
1
Hold
Consensus: Hold
Altman Z
3.0
Piotroski
4/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZEOOF buys
0
ABBV buys
0
No recent congressional trades found for ZEOOF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZEOOFABBV
Forward yield5.10%3.06%
Annual dividend / share$0.48$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%40.6%
Portfolio after 10y$6876.20M$102.3K
Annual income after 10y$6,626,566,862.72$24,771.77
Total dividends collected$6858.71M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusHoldBuy

Year-by-year: ZEOOF vs ABBV ($10,000, DRIP)

YearZEOOF PortfolioZEOOF Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$11,720$1,019.89$11,550$430.00+$170.00ZEOOF
2$14,774$2,234.21$13,472$627.96+$1.3KZEOOF
3$21,073$5,264.53$15,906$926.08+$5.2KZEOOF
4$36,584$14,035.40$19,071$1,382.55+$17.5KZEOOF
5$84,688$45,543.66$23,302$2,095.81+$61.4KZEOOF
6$287,681$197,064.83$29,150$3,237.93+$258.5KZEOOF
7$1,559,068$1,251,248.54$37,536$5,121.41+$1.52MZEOOF
8$14,343,060$12,674,857.55$50,079$8,338.38+$14.29MZEOOF
9$233,301,747$217,954,673.10$69,753$14,065.80+$233.23MZEOOF
10$6,876,199,732$6,626,566,862.72$102,337$24,771.77+$6876.10MZEOOF

ZEOOF vs ABBV: Complete Analysis 2026

ZEOOFStock

Zeon Corporation engages in the elastomers, specialty materials, and other businesses. The company offers synthetic rubbers, such as general-purpose rubbers for use in automobile tire applications; and various specialty rubbers, including NBR and hydrogenated NBR. It also provides synthetic latex comprising styrene-butadiene copolymer latex, polybutadiene, acrylonitrile butadiene copolymer latex, acrylate latex, and soap-free latex for use in processed paper, fiber treatment agents, adhesives, paints, and rubber gloves; and materials for adhesive tapes and hot melt adhesives, binder for traffic paints, and concrete admixtures. In addition, the company offers specialty chemicals, such as synthetic aroma chemicals for flavors and fragrances; cyclopentene, cyclopentanone, and other derivatives for chemical synthesis; intermediates for pharmaceuticals and agrochemicals; and solvents and cleaning agents. Further, it provides electronic materials, rechargeable battery materials, and toners for the production of semiconductors, etching gas, and materials used in rechargeable battery production; and specialty plastics that include cyclo olefin polymers and fine processed products with cyclo olefin polymer for use in optical lenses, medical devices, and various general-purpose engineering plastics. Additionally, the company develops, manufactures, and sells cardiovascular and gastrointestinal medical equipment, as well as nutritional products; and licenses butadiene recovery and butene purification process technologies in approximately 23 countries worldwide. It also offers PENTAM, a resource- and energy-saving molded product. The company was founded in 1950 and is headquartered in Tokyo, Japan.

Full ZEOOF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this ZEOOF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZEOOF vs SCHDZEOOF vs JEPIZEOOF vs OZEOOF vs KOZEOOF vs MAINZEOOF vs JNJZEOOF vs MRKZEOOF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.